<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120701</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 70 - CIRCULATE</org_study_id>
    <nct_id>NCT04120701</nct_id>
  </id_info>
  <brief_title>CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II</brief_title>
  <acronym>CIRCULATE</acronym>
  <official_title>CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of CIRCULATE trial is to improve care of patients after colon tumor surgery,
      based on an innovative marker: circulating tumor DNA.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year Disease-Free Survival in ctDNA positive patients</measure>
    <time_frame>3-years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1980</enrollment>
  <condition>Patients With Resected Stage II Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow-up within the study</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow-up outside the study</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6</intervention_name>
    <description>Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent obtained prior to any study specific procedures

          -  Age ≥ 18 years and ≤ 75 years

          -  Histologically confirmed stage II colon and high rectum adenocarcinoma excluding low
             and medium rectal cancers (tumor location ≥ 12 cm from the anal verge by endoscopy
             and/or above the peritoneal reflection at surgery are still eligible), without gross
             or microscopic evidence of residual disease after surgery with curative intent.
             Pathology report must be faxed to CRGA just after patient's randomization.

          -  At least 12 lymph nodes analyzed

          -  Patient with MSI + tumors can be included

          -  All patients must have been discussed in multidisciplinary meetings with a decision of
             not performing adjuvant chemotherapy

          -  No metastatic disease on CT-Scan and/or liver MRI done within 3 months before
             randomization.

          -  Randomization planned up to 7 weeks after curative R0 resection

          -  WHO performance Status &lt; 2

          -  No prior chemotherapy for colo-rectal cancer

          -  No prior abdominal or pelvic irradiation for colo-rectal cancer

          -  Life expectancy of ≥ 5 years

          -  Adequate haematological function: with neutrophils ≥ 1,500 /mm3, platelet count ≥
             100,000/mm3, hemoglobin ≥ 9 g/dL (5,6 mmol/l)

          -  Total bilirubin ≤ 1.5 x ULN (upper limit of normal)

          -  ASAT and ALAT ≤ 2.5 x ULN

          -  Alkaline phosphatase ≤ 2.5 x ULN

          -  Serum creatinine ≤ 120 µmol/L or creatinine clearance ≥50 ml/min according MDRD
             (Modification of Diet in Renal Disease)

          -  Carcinoembryogenic antigen (CEA) ≤ 1.5 x ULN after surgery (during screening period)

          -  Negative pregnancy test for registration(for women of childbearing age)

          -  Patient affiliated to a social security system

        Exclusion Criteria:

          -  T4b tumors

          -  Peripheral neuropathy &gt; grade 1

          -  Comorbidity influencing the 5 year patients' survival including clinically relevant
             cardiovascular disease,

          -  Ischemic myocardial infarction in the last year and/or unstable ischemic cardiopathy,

          -  Participation to another interventional study for postoperative therapy

          -  Partial or complete DPD deficiency

          -  Legal incapacity or physical, psychological social or geographical status interfering
             with the patient's ability to sign the informed consent or to finish the study

          -  Medical history of other concomitant or previous malignant disease, except adequately
             treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of
             the skin, or cancer in complete remission for ≥ 5 years,

          -  Lack of effective contraception in patients (men and/or women) of childbearing age,
             pregnant or breastfeeding women. Women of childbearing potential should agree to use a
             method of contraception during treatment of the trial and at least 4 months after
             discontinuation of oxaliplatin therapy and at least 30 days after discontinuation of
             5-fluorouracil. Men must agree to use a method of contraception during treatment and
             at least 6 months after stopping oxaliplatin therapy and at least 3 months after
             stopping 5-fluorouracil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julien TAIEB</last_name>
    <phone>+33 1 56 09 50 42</phone>
    <email>julien.taieb@egp.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fédération Francophone de Cancérologie Digestive</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Flore GEILLON</last_name>
      <phone>+33 3 80 39 34 04</phone>
      <email>flore.geillon@u-bourgogne.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

